Načítá se...
Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer
OBJECTIVE: To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3555305/ https://ncbi.nlm.nih.gov/pubmed/23372346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2012.12.07 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|